193 related articles for article (PubMed ID: 22587685)
1. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
Arefi M; García JL; Peñarrubia MJ; Queizán JA; Hermosín L; López-Corral L; Megido M; Giraldo P; de las Heras N; Vanegas RJ; Gutiérrez NC; Hernández-Rivas JM
Eur J Haematol; 2012 Jul; 89(1):37-41. PubMed ID: 22587685
[TBL] [Abstract][Full Text] [Related]
2. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
3. Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.
Gallagher G; Horsman DE; Tsang P; Forrest DL
Cancer Genet Cytogenet; 2008 Feb; 181(1):46-51. PubMed ID: 18262053
[TBL] [Abstract][Full Text] [Related]
4. Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms.
Hidalgo-Curtis C; Apperley JF; Stark A; Jeng M; Gotlib J; Chase A; Cross NC; Grand FH
Br J Haematol; 2010 Jan; 148(2):268-73. PubMed ID: 20085582
[TBL] [Abstract][Full Text] [Related]
5. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32).
Levine RL; Wadleigh M; Sternberg DW; Wlodarska I; Galinsky I; Stone RM; DeAngelo DJ; Gilliland DG; Cools J
Leukemia; 2005 Jan; 19(1):27-30. PubMed ID: 15496975
[TBL] [Abstract][Full Text] [Related]
6. Philadelphia chromosome-negative myeloproliferative neoplasm with a novel platelet-derived growth factor receptor-β rearrangement responsive to imatinib.
Cornfield D; Shah U; Cross N; Bennett C; Sun G
J Clin Oncol; 2012 Mar; 30(9):e109-11. PubMed ID: 22331939
[No Abstract] [Full Text] [Related]
7. Congenital and childhood myeloproliferative disorders with eosinophilia responsive to imatinib.
Abraham S; Salama M; Hancock J; Jacobsen J; Fluchel M
Pediatr Blood Cancer; 2012 Nov; 59(5):928-9. PubMed ID: 22488677
[TBL] [Abstract][Full Text] [Related]
8. KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.
Medves S; Duhoux FP; Ferrant A; Toffalini F; Ameye G; Libouton JM; Poirel HA; Demoulin JB
Leukemia; 2010 May; 24(5):1052-5. PubMed ID: 20164854
[No Abstract] [Full Text] [Related]
9. [Pediatric myeloid neoplasms associated with eosinophilia and platelet-derived growth factor receptor beta gene rearrangement: a case report and literature review].
Zhang XY; Liu TF; Li CW; Li QH; Zhu XF
Zhonghua Er Ke Za Zhi; 2018 Jan; 56(1):34-38. PubMed ID: 29342995
[No Abstract] [Full Text] [Related]
10. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
[TBL] [Abstract][Full Text] [Related]
11. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
[TBL] [Abstract][Full Text] [Related]
12. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).
Walz C; Haferlach C; Hänel A; Metzgeroth G; Erben P; Gosenca D; Hochhaus A; Cross NC; Reiter A
Genes Chromosomes Cancer; 2009 Feb; 48(2):179-83. PubMed ID: 19006078
[TBL] [Abstract][Full Text] [Related]
13. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
Rathe M; Kristensen TK; Møller MB; Carlsen NL
Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
[TBL] [Abstract][Full Text] [Related]
14. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF
Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151
[TBL] [Abstract][Full Text] [Related]
15. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.
Vizmanos JL; Novo FJ; Román JP; Baxter EJ; Lahortiga I; Larráyoz MJ; Odero MD; Giraldo P; Calasanz MJ; Cross NC
Cancer Res; 2004 Apr; 64(8):2673-6. PubMed ID: 15087377
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report.
Choi IK; Kim BS; Lee KA; Ryu S; Seo HY; Sul H; Choi JG; Sung HJ; Park KH; Yoon SY; Oh SC; Seo JH; Choi CW; Shin SW; Yoon SY; Cho Y; Kim YK; Kim YH; Kim JS
Am J Hematol; 2004 Dec; 77(4):366-9. PubMed ID: 15551277
[TBL] [Abstract][Full Text] [Related]
17. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
Walz C; Metzgeroth G; Haferlach C; Schmitt-Graeff A; Fabarius A; Hagen V; Prümmer O; Rauh S; Hehlmann R; Hochhaus A; Cross NC; Reiter A
Haematologica; 2007 Feb; 92(2):163-9. PubMed ID: 17296564
[TBL] [Abstract][Full Text] [Related]
18. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
Cross NC; Reiter A
Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
[TBL] [Abstract][Full Text] [Related]
20. Myeloid neoplasm with a novel cryptic PDGFRB rearrangement detected by next-generation sequencing.
Zimmermann N; Nassiri M; Zhou J; Miller AM; Zhang S
Cancer Genet; 2020 Jun; 244():55-59. PubMed ID: 32442889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
